What is Furmonertinib?

Furmonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring specific EGFR gene mutations.